Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
49 hedge funds and large institutions have $28.2M invested in Avadel Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 12 closing their positions.
3.08% more ownership
Funds ownership: 49.41% → 52.49% (+3.1%)
17% less funds holding
Funds holding: 59 → 49 (-10)
45% less capital invested
Capital invested by funds: $51M → $28.2M (-$22.8M)
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.3M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$688K |
| 3 |
Renaissance Technologies
New York
|
+$83.3K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$80.4K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$75.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$735K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$536K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$366K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$253K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$250K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
51
HRT Financial
New York
| – | -$33K | -13,174 | Closed |
|
|
EDRH
52
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$14K | -5,300 | Closed |
|
53
Bank of America
Charlotte,
North Carolina
| – | -$12K | -4,819 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$6.96K | -3,075 | -97% |
|
|
CA
55
Claro Advisors
Boston,
Massachusetts
| – | -$4K | -1,000 | Closed |
|
|
IA
56
IFP Advisors
Tampa,
Florida
| – | -$2K | -1,000 | Closed |
|
57
Barclays
London,
United Kingdom
| – | -$156 | -69 | -91% |
|
|
TRCT
58
Tower Research Capital (TRC)
New York
| – | -$41 | -18 | -10% |
|
AVDL Hedge Fund Activity: Q1 2019 in Review
49 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2019, worth a combined $28.2M — down 45% from $51M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AVDL and 2 opened new positions — a net loss of 10 holders — while 18 trimmed existing stakes and 8 added.
The largest buyer was Deutsche Bank, adding an estimated $1.3M. The largest seller was Fosun International, cutting an estimated $735K.
- 49 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2019, down from 59 in Q4 2018.
- Funds reported $28.2M of Avadel Pharmaceuticals stock for Q1 2019, down 45% quarter-over-quarter.
- 2 funds opened new Avadel Pharmaceuticals positions in Q1 2019 and 12 closed out, a net change of -10 holders.
- The largest Avadel Pharmaceuticals buyer in Q1 2019 was Deutsche Bank, an estimated $1.3M added.
- The largest Avadel Pharmaceuticals seller in Q1 2019 was Fosun International, an estimated $735K sold.
Based on aggregated 13F filings for Q1 2019.